Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAMBP | O95630 | 12/20 | 0.73 |
| ▸ | HPGDS | O60760 | 2/20 | 0.51 |
| ▸ | COPS5 | Q92905 | 8/20 | 0.49 |
| ▸ | PSMD14 | O00487 | 11/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | VEGFA | P15692 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13977394 | 0.81 | STAMBP (0.78) | STAMBPCOPS5PSMD14GAA | |
| SCHEMBL18539650 | 0.81 | STAMBP (0.76) | STAMBPHPGDSCOPS5PSMD14EGLN1 | |
| SCHEMBL18539634 | 0.80 | PSMD14 (0.68) | STAMBPHPGDSCOPS5PSMD14 | |
| SCHEMBL13978048 | 0.79 | PSMD14 (0.72) | STAMBPHPGDSCOPS5PSMD14 | |
| SCHEMBL18541956 | 0.79 | STAMBP (0.47) | STAMBPHPGDSCOPS5PSMD14 | |
| SCHEMBL18539646 | 0.77 | STAMBP (0.73) | STAMBPCOPS5PSMD14GAA | |
| SCHEMBL18539648 | 0.77 | STAMBP (0.77) | STAMBPCOPS5PSMD14 | |
| SCHEMBL18539644 | 0.76 | PSMD14 (0.74) | STAMBPCOPS5PSMD14KDM4E | |
| SCHEMBL18539647 | 0.76 | STAMBP (0.74) | STAMBPCOPS5PSMD14 | |
| SCHEMBL18539638 | 0.75 | PSMD14 (0.74) | STAMBPCOPS5PSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019238817-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING RPN11 | UNIVERSITY OF DUNDEE (GB) | 2019-12-19 | — | — | WO | disclosed |
| US-10005735-B2 | Inhibitors of RPN11 | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005735-B2 | Inhibitors of RPN11 | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-06-26 | — | — | US | disclosed |
| WO-2017031255-A1 | INHIBITORS OF RPN11 | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20170050931-A1 | INHIBITORS OF RPN11 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-02-23 | — | — | US | disclosed |
| US-20170050931-A1 | INHIBITORS OF RPN11 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-02-23 | — | — | US | disclosed |
| US-20140235548-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | CLEAVE BIOSCIENCES, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235548-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | CLEAVE BIOSCIENCES, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2012158435-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | ZHOU HAN-JIE (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050931-A1 | INHIBITORS OF RPN11 | POLR2A, RPP30, RPIA | STAMBP 3835/4885HPGDS 3941/4885COPS5 700/4885 |
| US-20140235548-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | USP24, USP36, USP39 | STAMBP 137/4885HPGDS 3431/4885COPS5 39/4885 |
| US-10005735-B2 | Inhibitors of RPN11 | POLR2A, RPP30, RPIA | STAMBP 3835/4885HPGDS 3941/4885COPS5 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.